EMV Capital
EMV Capital plc is a leading deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies. They invest in, manage, and strengthen early-stage IP-rich companies with a focus on generating superior returns for investors. EMV Capital employs a proactive management style, aiming to advance companies to critical value inflection points.
AI VIVO, AllFocal Optics, Axol Bioscience, Beam, Cambridge GaN Devices, Cambridge Nutraceuticals, Camstent, Cetromed, Closed Loop Medicine, Converge, Cytovale, DeepTech Recycling, Dname-iT, Dogtooth Technologies, Echion Technologies, EpiBone, Exonate, FocalPoint Positioning, FOx Biosystems, G-Tech Medical, Glycotest, IESO Digital Health, Infinitopes, Kalium Health, Lungfish, Myrtle.ai, Nanotech Industrial Solutions, NoBACZ, NU Quantum, NunaBio, OctaiPipe, Oncocidia, Oxford Space Systems, Paragraf, PatientSource, PDS Biotechnology, Pencil Biosciences, PervasID, PharmEnable, Plastometrex, Plumis, PointGrab, Porotech, ProAxsis, Psyomics, Q-Bot, Qkine, QuantalX Neuroscience, RoboK, SageTech Medical, Semarion, Signaloid, Sofant Technologies, Sorex Sensors, Spotta, Strolll, Techspert, Transparent Choice, Tripism, Undo, Ventive, Vortex, Wanda Health, Xampla